pulmonary function in young children with cystic fibrosis (CF).

[Guest guest]

Subject: CF: Growth and nutritional indexes in early life predict pulmonary

function in cystic fibrosis (CF).

J Pediatr 2003;142:624-30

June 2003 . Volume 142 . Number 6

Original Articles

Growth and nutritional indexes in early life predict

pulmonary function in cystic fibrosis

W. Konstan, MD [MEDLINE LOOKUP]

M. , PhD [MEDLINE LOOKUP]

Ellen B. Wohl, MD [MEDLINE LOOKUP]

Marcia Stoddard, BS [MEDLINE LOOKUP]

Matousek, MS [MEDLINE LOOKUP]

S. Wagener, MD [MEDLINE LOOKUP]

A. , MBChB [MEDLINE LOOKUP]

Wayne J. , MD [MEDLINE LOOKUP]

Abstract

Objective

To determine the relation of growth and nutritional

status to pulmonary function in young children with

cystic fibrosis (CF).

Study design

The relation of weight-for-age (WFA), height-for-age

(HFA), percent ideal body weight (%IBW), and signs of

lung disease at age 3 years with pulmonary function at

age 6 years was assessed in 931 patients with CF.

Associations of changes in WFA from age 3 to 6 on

pulmonary function were also assessed.

Results

WFA, HFA, and %IBW were poorly associated with lung

disease at age 3 years, but all were strongly

associated with pulmonary function at age 6 years.

Those with WFA below the 5th percentile at age 3 had

lower pulmonary function at age 6 compared with those

above the 75th percentile (FEV1: 86 ± 20 [sD] versus

102 ± 18 % predicted, respectively). Pulmonary

function was highest in those whose WFA remained >10th

percentile from age 3 to 6 (FEV1: 100 ± 19 %

predicted) and lowest in those who remained <10th

percentile (84 ± 21 % predicted). Patients with signs

and symptoms of lung disease at age 3 years had lower

pulmonary function at age 6 years.

Conclusions

Aggressive intervention early in life aimed at growth

and nutrition and/or lung disease may affect pulmonary

function. (J Pediatr 2003;142:624-30)

Publishing and Reprint Information

From the Department of Pediatrics, Rainbow Babies and

Children's Hospital and Case Western Reserve

University School of Medicine, Cleveland, Ohio;

Medical Affairs, Genentech, South San Francisco,

California; the Department of Pediatrics, Children's

Hospital and Harvard Medical School, Boston,

Massachusetts; the Department of Pediatrics, The

Children's Hospital and University of Colorado School

of Medicine, Denver, Colorado; and the Departments of

Pediatrics and Physiology, University of Arizona,

Tucson, Arizona.

Genentech, Inc, funds the Epidemiologic Study of

Cystic Fibrosis.

Drs Konstan, Wohl, Wagener, and are members of

the scientific advisory board for the Epidemiologic

Study of Cystic Fibrosis and have received grants and

other support from Genentech, Inc.

Submitted for publication Jan 28, 2002;

revisions received Aug 13, 2002, and Dec 23, 2002;

accepted Jan 16, 2003.

Reprint requests: W. Konstan, MD, Rainbow

Babies and Children's Hospital, 11100 Euclid Ave,

Cleveland, OH 44106. E-mail: mwk3@... .

for the Investigators Coordinators of the

Epidemiologic Study of Cystic Fibrosis

Copyright © 2003, Mosby, Inc. All rights reserved.

Peace

Torsten, dad of Fiona 6wcf and Sebastian newborn wocf

e-mail: torstenkrafft@...